Lauffer et al. discuss the possibilities that antisense oligonucleotide (ASO) approaches can bring to treating rare genetic diseases. The authors outline considerations and barriers to their implementation, and how these might be overcome.
- Marlen C. Lauffer
- Willeke van Roon-Mom
- Annemieke Aartsma-Rus